IL-34/TREM2 modulates microglia-mediated inflammation and provides neuroprotection in a mouse model of sporadic Alzheimer's disease

J Alzheimers Dis. 2025 Apr;104(3):875-885. doi: 10.1177/13872877251320418. Epub 2025 Mar 2.

Abstract

BackgroundAs a recently identified cytokine, interleukin-34 (IL-34) is predominantly produced by neurons and functions as a modulator for glial functions. Emerging evidence indicates that IL-34 exerted neuroprotective effects in Alzheimer's disease (AD), but the underlying mechanism remained elusive.ObjectiveTo uncover the mechanisms by which IL-34 provides neuroprotection in AD.MethodsUsing senescence-accelerated mouse prone substrain 8 (SAMP8) mice, a well-established model for sporadic AD, we investigated the dynamic changes in brain IL-34 concentrations during AD progression. Afterwards, SAMP8 mice received a 4-week continuous intracerebroventricular infusion of IL-34. Morris water maze test was employed to assess the spatial cognitive functions. Neuronal and synaptic markers, oxidative stress makers, pro-inflammatory cytokines and glial activation markers in the brains of SAMP8 mice were measured. Finally, amyloid-β (Aβ)42-stimulated primary microglia, lentivirus-mediated gene knockdown strategy and co-immunoprecipitation assay were utilized to uncover the possible mechanisms by which IL-34 exerted neuroprotection in AD.ResultsIn SAMP8 mice, we revealed that brain IL-34 concentrations gradually decreased during AD progression. A 4-week continuous intracerebroventricular infusion of IL-34 rescued spatial cognitive impairments, ameliorated neuronal and synaptic damage, and suppressed oxidative stress and microglia-mediated inflammation in the brains of SAMP8 mice. Using Aβ42-stimulated primary microglia, we demonstrated for the first time that IL-34 suppressed microglial NLRP3 inflammasome activation and pro-inflammatory cytokines release by interacting with triggering receptor expressed on myeloid cells 2 (TREM2), a key regulator of microglial functions.ConclusionsThese findings uncover the mechanisms by which IL-34 provides neuroprotection in AD, indicating that IL-34/TREM2 signaling may represent a novel therapeutic strategy for this devastating disease.

Keywords: Alzheimer's disease; IL-34; NLRP3; TREM2; microglia; neuroinflammation.

MeSH terms

  • Alzheimer Disease* / metabolism
  • Alzheimer Disease* / pathology
  • Amyloid beta-Peptides
  • Animals
  • Brain / drug effects
  • Brain / metabolism
  • Brain / pathology
  • Disease Models, Animal
  • Inflammation* / metabolism
  • Interleukins* / metabolism
  • Interleukins* / pharmacology
  • Male
  • Membrane Glycoproteins* / metabolism
  • Mice
  • Microglia* / drug effects
  • Microglia* / metabolism
  • Neuroprotection* / drug effects
  • Neuroprotection* / physiology
  • Neuroprotective Agents
  • Oxidative Stress / drug effects
  • Receptors, Immunologic* / metabolism

Substances

  • Interleukins
  • Trem2 protein, mouse
  • interleukin-34, mouse
  • Membrane Glycoproteins
  • Receptors, Immunologic
  • Amyloid beta-Peptides
  • Neuroprotective Agents